
EASL Podcasts
European Association for the Study of the Liver 152 episodes Nov 11, 2026
The EASL Podcast collection brings together Talk Liver to Me, EASL’s exclusive original podcast, alongside educational audio content adapted from EASL Studio, DeepDive webinars, and Policy Dialogues. Stay informed with expert insights, practical discussions, and the latest knowledge in hepatology — anytime, anywhere.
Episodes

Talk Liver To Me - Cholangiocarcinoma surveillance in PSC: What should we do now and what’s coming next?
Discover how clinicians are approaching screening and surveillance in PSC today. From imaging and endoscopy to the promise of new biomarkers, this episode highlights key tools, ongoing challenges, and future directions in improving early detection of cholangiocarcinoma. Host: Debbie Shawcross (King's College London) Guests: Jesús Bañales (Donostia University Hospital), Gideon Hirschfield (T

EASL DeepDive: AI-Enabled Clinical Trials: Opportunities, Evidence and Oversight
Artificial intelligence (AI) is opening new opportunities to improve the design, efficiency, and evidence generation of clinical trials. This EASL DeepDive examines its applications in patient selection, stratification, and trial workflows, as well as the emerging role of digital twins in simulating treatment responses. Particular attention is given to the use of AI-enabled real-world data to stre

Talk Liver To Me - Hepatocellular Carcinoma: Who to screen, when, and how?
Hepatocellular carcinoma (HCC) surveillance is a cornerstone of liver disease management, yet uncertainty persists around who to screen, when to initiate surveillance, and which modalities to use. Evolving risk profiles and variation across guidelines have added complexity to clinical decision-making. In this podcast, we revisit the fundamentals of HCC screening, focusing on practical, evidence-ba

Talk Liver To Me - Psychohepatology: Are we overlooking mental health in liver disease care?
This episode explores psychohepatology, examining the gut–liver–brain axis and the bidirectional links between liver disease and mental health. Discussion covers addiction biology, the impact of trauma and post-traumatic stress disorder (PTSD) on alcohol use, and the high prevalence of depression and anxiety in cirrhosis, highlighting integrated approaches to liver and mental health care. Host: Ma

EASL DeepDive: Key Updates in the EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
This EASL Deep Dive explores key updates from the EASL Clinical Practice Guidelines on hepatocellular carcinoma (HCC), with a practical focus on diagnosis and treatment selection. Experts will discuss evolving imaging and diagnostic criteria, patient selection for surgery and locoregional therapies, and how to adapt management according to response to systemic treatment. The session will also high

Talk Liver To Me - Resmetirom and Semaglutide in MASH: Who, when and how to monitor?
This episode of Talk Liver to Me explores the practical use of resmetirom and semaglutide in MASH, based on the 2026 EASL–EASD–EASO Guidance. Experts discuss who may benefit from treatment, when to initiate therapy, and how to monitor response and efficacy in clinical practice. Host: Debbie Shawcross (EASL) Guests: Andreea Ciudin (EASO), Amalia Gastaldelli (EASD), Frank Tacke (EASL) This episode

Talk Liver To Me - Africa’s Liver Crisis: Why Is No One Talking About It?
Liver disease represents a major and under-recognised public health challenge across Africa, driven by a complex interplay of viral hepatitis, rising metabolic dysfunction-associated steatotic liver disease, and a high burden of hepatocellular carcinoma (HCC). Despite this, awareness, surveillance, and access to care remain limited. In this podcast, we explore the evolving epidemiology of liver di

EASL DeepDive: Utility and challenges of genetic testing in PFIC
This webinar explores the role of genetic testing in diagnosing Progressive Familial Intrahepatic Cholestasis (PFIC). Attendees will review key test types, understand the principles behind modern genomic technologies, and learn how to position these tests in the diagnostic approach of a person with a suspicion of PFIC and how to navigate common challenges in interpreting genetic results. The sessi

Talk Liver To Me - What are the Dos and Don'ts in Acute Liver Failure?
Acute liver failure (ALF) is a rare but life-threatening condition requiring rapid recognition and decisive management. Early decisions around investigation, escalation, and referral can significantly impact outcomes. Despite advances in care, variation in practice and avoidable pitfalls remain common. In this podcast, we take a practical, case-based approach to the key “dos and don’ts” in ALF man

Talk Liver To Me - Endohepatology: Added value or added complexity?
Endohepatology is emerging as a novel approach to liver disease assessment, with the potential to combine EUS-guided liver biopsy, portal pressure measurement, and variceal evaluation within a single session. This “one-stop shop” model could streamline diagnostic pathways and enable integrated, real-time clinical decision-making. However, this innovation comes at a time when hepatology is moving i

Talk Liver To Me - What nobody tells you about starting a research group
Early-career researchers and clinician-scientists play a central role in advancing hepatology research and innovation, yet the transition to independence often comes with challenges that extend beyond scientific expertise. Building a research programme, leading teams, securing funding, and developing a sustainable academic career require skills that are rarely addressed during formal training. In

Talk Liver To Me - Global Updates on Hepatitis E: How Should We Manage Acute and Chronic Infection?
Hepatitis E is a globally prevalent infection with diverse clinical manifestations, ranging from self-limiting acute hepatitis to chronic infection in immunosuppressed patients. Its presentation and epidemiology vary significantly between regions, influencing diagnostic and management strategies. Despite increasing recognition, uncertainty remains around who to test, when to treat, and how to mana











